Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic

Plasma cell tumors

Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option

PDF) Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Current status of autologous stem cell transplantation for multiple myeloma

View of Ciltacabtagene Autoleucel (Carvykti)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma, Experimental Hematology & Oncology

JPatientRepOutcomes (@JPRO_ISOQOL) / X

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma - ScienceDirect

Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial - ScienceDirect

Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience - ScienceDirect

OUH - Oslo Myeloma Center